Amneal Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Amneal Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 19.3%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento anual de 10.5%. Los ingresos han ido creciendo a una tasa media de 7.3% al año.

Información clave

16.9%

Tasa de crecimiento de los beneficios

24.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	7.3%
Tasa de crecimiento de los ingresos	7.5%
Rentabilidad financiera	n/a
Margen neto	-6.8%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Amneal Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:2DT Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	2,495	-169	440	165
31 Dec 23	2,394	-84	430	164
30 Sep 23	2,386	10	423	160
30 Jun 23	2,312	-2	410	169
31 Mar 23	2,272	-135	403	182
31 Dec 22	2,212	-130	400	196
30 Sep 22	2,139	-132	395	206
30 Jun 22	2,122	-134	386	204
31 Mar 22	2,098	2	373	206
31 Dec 21	2,094	11	366	202
30 Sep 21	2,067	14	353	203
30 Jun 21	2,058	9	345	199
31 Mar 21	1,987	-17	339	192
31 Dec 20	1,993	91	327	180
30 Sep 20	1,880	62	316	175
30 Jun 20	1,739	-194	297	168
31 Mar 20	1,679	-199	283	171
31 Dec 19	1,626	-362	290	188
30 Sep 19	1,727	-339	287	197
30 Jun 19	1,825	-67	298	202
31 Mar 19	1,834	-69	287	204
31 Dec 18	1,663	-21	228	194
30 Sep 18	1,459	155	184	180
30 Jun 18	1,237	149	136	179
31 Mar 18	1,083	168	106	176
31 Dec 17	1,034	168	109	171
30 Sep 17	1,039	54	113	171
31 Dec 16	1,018	207	119	179
31 Dec 15	866	169	110	137
31 Dec 14	786	177	85	107

Ingresos de calidad: 2DT actualmente no es rentable.

Margen de beneficios creciente: 2DT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 2DT no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 19.3% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 2DT en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 2DT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (4%).

Rentabilidad financiera

Alta ROE: El pasivo de 2DT supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Amneal Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Recent updates

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors

Amneal Pharmaceuticals, Inc. Appoints Deborah M. Autor to Board of Directors

Amneal Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Amneal Pharmaceuticals, Inc. Announces Class Action Lawsuit Settlement Updates

Amneal Pharmaceuticals, Inc. Launches LYVISPAH for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.045 profit in 1Q 2021)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

Amneal Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Amneal Pharmaceuticals, Inc. Reports Asset Impairment Charges for the Three Months Ended December 31, 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Amneal Pharmaceuticals, Inc. Receives Approval of Releukotm

Amneal Pharmaceuticals, Inc. Expands Injectables Portfolio with 4 New Products

Amneal Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2021

Co-Founder recently bought €553k worth of stock

Co-Founder recently bought €553k worth of stock

Amneal Pharmaceuticals, Inc. Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

Second quarter 2021 earnings released: EPS US$0.098 (vs US$0.081 loss in 2Q 2020)

Amneal Pharmaceuticals, Inc. Receives Approval for Generic TobraDex

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

Amneal Pharmaceuticals, Inc Announces That the Food and Drug Administration Recently Accepted Amneal’s 505(B)(2) New Drug Application for A Newly Licensed Dihydroergotamine

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended March 31, 2021

First quarter 2021 earnings released: EPS US$0.045 (vs US$0.78 in 1Q 2020)

New 90-day high: €5.04

Desglose de ingresos y gastos
Beta